Pfizer Inc. (FRA:PFEB)
Germany · Delayed Price · Currency is EUR | Market Cap | 127.41B +10.2% |
| Revenue (ttm) | 55.85B -0.2% |
| Net Income | 3.80B -59.7% |
| EPS | 0.67 -59.9% |
| Shares Out | n/a |
| PE Ratio | 33.53 |
| Forward PE | 8.98 |
| Dividend | 0.48 (7.18%) |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | n/a |
| Open | 6.70 |
| Previous Close | 6.60 |
| Day's Range | 6.65 - 6.70 |
| 52-Week Range | 5.80 - 8.25 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Pfizer price target raised to $27 from $26 at BofA
BofA raised the firm’s price target on Pfizer (PFE) to $27 from $26 and keeps a Neutral rating on the shares. Despite a “solid” Q2, the firm expects Pfizer to…
Pfizer Earnings Call Transcript: Q2 2026
Q2 2026 results exceeded expectations with strong non-COVID revenue growth, robust performance from acquired products, and continued R&D progress. Full-year revenue guidance was raised, cost savings initiatives expanded, and the dividend commitment reaffirmed.
Pfizer Earnings release: Q2 2026
Pfizer released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Pfizer Slides: Q2 2026
Pfizer has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Pfizer Quarterly report: Q2 2026
Pfizer has published its Q2 2026 quarterly earnings report on August 4, 2026.
Pfizer Stock (PFE) Falls on 2026 Sales Outlook as Cancer Drugs Fuel Q2 Beat
Pfizer’s ($PFE) shares edged lower during Tuesday’s pre-market session after the U.S. pharma giant raised its full-year 2026 sales outlook but still fell below the Wall Street consensus. This took…
Pfizer Post Loss on Higher Revenue
Pfizer swung to a second-quarter loss but posted higher revenue, as market growth in its oncology business offset some declines in its Covid-19 products.
Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
Pfizer reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, citing the stronger-than-expected performance of non-Covid products. The company is now expe...
Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings
Pfizer beats earnings forecasts for the second quarter, while BioNTech's results miss expectations due to weak Covid vaccine demand.
Pfizer reports Q2 adjusted EPS 77c, consensus 68c
Reports Q2 revenue $15B, consensus $14.39B. “Pfizer (PFE) had another strong quarter, delivering on our financial commitments and advancing our strategy. Our launched and acquired products performed w...
Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
Pfizer beat Wall Street estimates for second-quarter profit on Tuesday, driven by strong demand for its blood thinner, Eliquis.
Pfizer backs FY26 adjusted EPS view $2.80-$3.00, consensus $2.95
Raises FY26 revenue view to $60.5B-$62.5B from $59.5B-$62.5B, consensus $61.74B.
Pfizer announces expansion of productivity enhancement Initiatives
Announces additional anticipated productivity enhancement savings of $2.5 associated with ongoing initiatives, expected to be realized from 2027 through 2029.
Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffi...
5 Things to Know Before the Stock Market Opens on Monday
Stock futures are pointing to a higher open to kick off August trading as investors look ahead to a packed week of earnings reports; oil prices are tumbling after the U.S. paused strikes on Iran over ...
Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials
Pfizer said on Thursday its oral drug helped restore skin color in patients with a common form of vitiligo in two late-stage trials, paving the way for regulatory submissions seeking approval in the...
Pfizer says LITFULO studies meet co-primary endpoints
Pfizer (PFE) announced topline results from two Phase 3 trials evaluating the efficacy and safety of LITFULO once daily in patients with both active and stable nonsegmental vitiligo and who…
Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from two Phase 3 trials evaluating the efficacy and safety of LITFULO once daily in patients with both activ...
EC authorizes Pfizer, BioNTech XFG-adapted COVID-19 vaccine in EU
Pfizer (PFE) and BioNTech (BNTX) announced that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for a...
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Commission (EC) has granted marketing authori...
Pfizer's prostate cancer drug combination gets US FDA priority review
Pfizer said on Wednesday the U.S. Food and Drug Administration has granted priority review to its application seeking expanded approval for its prostate cancer treatment combination.
FDA grants priority review for Pfizer’s Talzena plus Xtandi
Pfizer (PFE) announced that the U.S. Food and Drug Administration accepted for Priority Review a supplemental New Drug Application for TALZENNA, an oral poly ADP-ribose polymerase inhibitor, in combin...
FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA...
Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later
President Donald Trump said on Tuesday all generic drugs being brought into the U.S. will continue having a tariff of 0% for two years starting from August 1, after which the tariff rate wi...
Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
U.S. drugmaker Pfizer has temporarily discontinued Premarin vaginal cream in India, shrinking estrogen therapy options for millions of women experiencing menopause-related symptoms in the country.